Pacific Biosciences
PACB
86 hedge funds and large institutions have $230M invested in Pacific Biosciences in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 16 closing their positions.
12% more capital invested
Capital invested by funds: $206M → $230M (+$24.7M)
2% less funds holding
Funds holding: 88 → 86 (-2)
10% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 29
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
29% less call options, than puts
Call options by funds: $512K | Put options by funds: $721K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$3.04M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.14M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.41M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.03M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$933K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.56M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.35M |
| 3 |
Millennium Management
New York
|
-$2.33M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.11M |
| 5 |
Morgan Stanley
New York
|
-$1.65M |
PACB Hedge Fund Activity: Q2 2014 in Review
86 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2014, worth a combined $230M — up 12% from $206M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PACB and 14 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 26 added.
The largest buyer was Raging Capital Management, adding an estimated $3.04M. The largest seller was Deerfield Management, cutting an estimated $3.56M.
- 86 institutional investors held Pacific Biosciences (PACB) as of Q2 2014, down from 88 in Q1 2014.
- Funds reported $230M of Pacific Biosciences stock for Q2 2014, up 12% quarter-over-quarter.
- 14 funds opened new Pacific Biosciences positions in Q2 2014 and 16 closed out, a net change of -2 holders.
- The largest Pacific Biosciences buyer in Q2 2014 was Raging Capital Management, an estimated $3.04M added.
- The largest Pacific Biosciences seller in Q2 2014 was Deerfield Management, an estimated $3.56M sold.
Based on aggregated 13F filings for Q2 2014.